These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19395115)

  • 1. Pioglitazone as adjuvant therapy in chronic hepatitis C: sequential rather than concomitant administration with pegylated interferon and ribavirin?
    Serfaty L; Fartoux L; Poupon R
    J Hepatol; 2009 Jun; 50(6):1269-71. PubMed ID: 19395115
    [No Abstract]   [Full Text] [Related]  

  • 2. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance.
    Khattab M; Emad M; Abdelaleem A; Eslam M; Atef R; Shaker Y; Hamdy L
    Liver Int; 2010 Mar; 30(3):447-54. PubMed ID: 19919569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin.
    Overbeck K; Genné D; Golay A; Negro F;
    J Hepatol; 2008 Aug; 49(2):295-8. PubMed ID: 18555553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin, hepatitis C, and insulin resistance: sufficient evidence?
    Yilmaz Y; Yonal O; Imeryuz N
    Hepatology; 2009 Dec; 50(6):2054-5; author reply 2055. PubMed ID: 19937685
    [No Abstract]   [Full Text] [Related]  

  • 5. [Combination therapy of interferon plus ribavirin for chronic hepatitis C].
    Asahina Y; Izumi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):467-73. PubMed ID: 15359843
    [No Abstract]   [Full Text] [Related]  

  • 6. [Two-step interferon rebound therapy].
    Kato M; Yuki N; Iyoda K; Yamamoto K; Hayashi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):497-501. PubMed ID: 15359849
    [No Abstract]   [Full Text] [Related]  

  • 7. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
    Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
    [No Abstract]   [Full Text] [Related]  

  • 8. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
    Henry MJ
    N Engl J Med; 2005 Sep; 353(11):1182-3; author reply 1182-3. PubMed ID: 16167381
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.
    Grasso A; Malfatti F; De Leo P; Martines H; Fabris P; Toscanini F; Anselmo M; Menardo G
    J Hepatol; 2009 Dec; 51(6):984-90. PubMed ID: 19695729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Patient, 50, with chronic hepatitis C genotype 1 infection. Therapeutic success despite poor prognosis].
    Klinker H
    MMW Fortschr Med; 2003 Oct; 145(41):39-40. PubMed ID: 14655480
    [No Abstract]   [Full Text] [Related]  

  • 11. ADVANCE study begins enrollment.
    AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of cirrhotics].
    Galdame O; Jorge A; Sordá J
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S42-5. PubMed ID: 20214300
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The study of optimal treatment in patients with refractory chronic hepatitis C].
    Chen XY; Zhang YH
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):488-9. PubMed ID: 19912679
    [No Abstract]   [Full Text] [Related]  

  • 15. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 16. Viral kinetics in the treatment of chronic hepatitis C.
    Layden-Almer JE; Cotler SJ; Layden TJ
    J Viral Hepat; 2006 Aug; 13(8):499-504. PubMed ID: 16901279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
    Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
    Pawłowska M; Palewicz E; Halota W
    Przegl Epidemiol; 2006; 60(1):71-7. PubMed ID: 16758742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of pegylated interferon and ribavirin in Korean patients with chronic hepatitis C virus infection].
    Kang MJ; Jung EU; Park SW; Choi P; Kim JH; Park SJ; Park ET; Lee YJ; Lee SH; Seol SY
    Korean J Hepatol; 2008 Sep; 14(3):318-30. PubMed ID: 18815455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads.
    Sezaki H; Suzuki F; Akuta N; Yatsuji H; Hosaka T; Kobayashi M; Suzuki Y; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    Intervirology; 2009; 52(1):43-8. PubMed ID: 19372703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.